The data concerning therapy responses suggested that reduced TTC17 conferred better pathological complete response (pCR) and five-year RFS rates in BC patients subjected to paclitaxel-based chemotherapy in the neoadjuvant and adjuvant settings, respectively (Fig. 6n, o). Here, TTC17 is linked to breast cancer.